N4 Pharma plc’s subsidiary Nanogenics Ltd. has signed a contract to start the formulation and sequence selection work to prepare its ECP-105 product for testing in preclinical studies.
SUMOylation is a post-translational modification implicated in DNA damage repair that has been linked to the lack of efficacy of some therapies commonly used for the treatment of leukemia.
Coya Therapeutics Inc. intends to expand proposed indications for COYA-302 beyond amyotrophic lateral sclerosis (ALS) to include frontotemporal dementia (FTD) and Parkinson’s disease.
Cellectar Biosciences Inc. has released promising preclinical data for its proprietary novel α-emitting phospholipid radiotherapeutic conjugate, CLR-121225 (225Ac-CLR-121225), an actinium-labeled phospholipid ether, in refractory pancreatic cancer mouse xenograft models.
Huazhong University of Science and Technology and affiliated organizations have explored the role of microRNA-218-5p (miR-218-5p) in Parkinson’s disease (PD).
Researchers at Mount Sinai have identified a unique neuron type that could explain vulnerability in Parkinson’s disease and thus help unravel the neuronal complexity of this disorder – hopefully leading to more precise and effective therapies. The findings, published in Science Advances on Jan. 10, 2024, provide new insights into the genetic causes and changes occurring in substantia nigra during PD pathogenesis.
Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.
RSS
